Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Insider awards to Guardant Health director Alex M. Azar II
Alex M. Azar II, identified as a director of Guardant Health (GH), received equity awards on 09/12/2025. The filing reports a stock option to purchase 10,532 shares with an exercise price of $54.895 and an option term through 09/12/2035. The option and a separate restricted stock unit (RSU) award for 6,604 shares both vest over four years (25% one year after grant, remainder monthly over three years). The Form 4 was signed by an attorney-in-fact on 09/26/2025. The filing shows direct beneficial ownership following the grants: 10,532 option shares and 6,604 RSU shares.
Alex M. Azar II filed an initial Form 3 reporting his role with Guardant Health, Inc. (GH) as a Director. The event date requiring the statement is 09/12/2025. The filing discloses 0 shares of common stock beneficially owned, reported as direct ownership. The form is signed by an attorney-in-fact on behalf of Mr. Azar on 09/26/2025.
Guardant Health, Inc. announced that it will host an Investor Day on September 24, 2025, beginning at 9:00 a.m. Eastern time in New York City. The event will feature presentations by co-Chief Executive Officers Helmy Eltoukhy and AmirAli Talasaz, along with other executive leaders.
The company plans to highlight its operations and provide updates on key strategic priorities and financial outlook. A live and archived webcast of the presentation will be available through the Investors section of Guardant Health’s website, allowing both in-person and remote participants to follow the event.
Manuel Hidalgo Medina, a director of Guardant Health, Inc. (GH), reported transactions dated 09/17/2025 showing the acquisition of 232 restricted stock units (RSUs) at $0 pursuant to vesting (Transaction Code M). The Form 4 shows 1,083 shares of common stock held following a separate non-derivative entry and 7,889 shares beneficially owned following the reported derivative transactions. The filing notes the RSU award was granted on July 17, 2024 and vests over four years: 25% vested at the one-year anniversary and the remaining 75% vests monthly over the following three years. The form is signed by an attorney-in-fact on 09/18/2025.
Tariq Musa, a director of Guardant Health, reported two transactions in September 2025. On 09/15/2025 249 restricted stock units (RSUs) vested, converting into 249 common shares and increasing his derivative/underlying holdings. On 09/17/2025 he sold 116 common shares at $55.63 per share, reducing his direct common stock holdings from 7,707 to 7,591 shares. After these transactions, he beneficially owns 7,591 common shares directly and 4,498 shares underlying RSUs.
Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported an RSU vesting and a subsequent small sale of shares. On 09/15/2025 a restricted stock unit award vested for 68 shares at no cash price. Two days later, on 09/17/2025, the reporting person sold 26 shares at $55.63 per share. Beneficial ownership reported after the sale was 18,281 shares on a direct basis. The filing was executed by attorney-in-fact John G. Saia on 09/17/2025. The RSU award follows a vesting schedule that began with 25% vesting on October 15, 2022, with the remaining 75% vesting monthly over the following three years.
Guardant Health director and Chief Legal Officer John G. Saia reported transactions on Form 4 showing equity activity dated 09/15/2025. The filing discloses that 1,019 restricted stock units vested and were converted into 1,019 shares, of which the company retained a portion to satisfy tax withholding (the filing states the retained amount equaled the tax liability). Also on 09/15/2025 Mr. Saia sold 535 shares at $54.79 per share. After these transactions he beneficially owned 45,967 shares of Guardant Health common stock.
Insider stock changes at Guardant Health (GH): On 09/15/2025 Chief Information Officer Kumud Kalia had 638 restricted stock units vest, resulting in 638 shares issued to her and retained 324 shares that were sold to satisfy tax withholding at a price of $54.79 per share. After these transactions Kalia beneficially owns 19,488 shares of Common Stock. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Chris Freeman, Chief Commercial Officer of Guardant Health (GH), reported insider transactions dated 09/15/2025. The filing shows 1,402 restricted stock units vested and were treated as an acquisition at $0, increasing his beneficial ownership to 50,223 shares before subsequent disposition. The company retained 1,402 shares to satisfy tax withholding related to the vesting. Separately, Freeman disposed of 594 shares at $54.79, leaving him with 49,629 shares beneficially owned after the reported transactions.
Craig Eagle, Chief Medical Officer of Guardant Health, reported transactions on 09/15/2025 related to the vesting of restricted stock units (RSUs) granted June 9, 2023. A tranche of 1,402 shares vested and were delivered at no cash price to the reporting person. To satisfy tax withholding obligations, the company retained 711 shares at an effective withholding price of $54.79 per share.
After these transactions the reporting person beneficially owned 37,482 shares of Guardant Health common stock. The RSU award vests over three years (33% vested June 15, 2024; remaining 67% vests in equal quarterly installments over the following two years). The Form 4 was signed by an attorney-in-fact on 09/17/2025.